Fairmount Funds Management LLC

Q2 2025 13F Holdings

  • Location
    west conshohocken, PA
  • Num holdings

    17

  • Value ($000)

    $771,902

  • Date Filed
    08/14/2025
  • Form type
    13F-HR
  • CIK
    0001802528
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q2 2025 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
APGE
APGE

APOGEE THERAPEUTICS INC

COM
03770N101
$88.97 M
12 %

2,048,647

AXSM
AXSM

AXSOME THERAPEUTICS INC

COM
05464T104
$85.10 M
11 %

815,176

ELVN
ELVN

ENLIVEN THERAPEUTICS INC

COM
29337E102
$74.45 M
10 %

3,711,444

SRRK
SRRK

SCHOLAR ROCK HLDG CORP

COM
80706P103
$64.61 M
8 %

1,824,031

SYRE
SYRE

SPYRE THERAPEUTICS INC

COM NEW
00773J202
$60.15 M
8 %

4,018,101

NUVL
NUVL

NUVALENT INC

COM
670703107
$55.51 M
7 %

727,563

DNTH
DNTH

DIANTHUS THERAPEUTICS INC

COM
252828108
$50.43 M
7 %

2,707,191

---

KINIKSA PHARMACEUTICALS INTL

ORD SHS CL A
G52694109
$49.05 M
6 %

1,772,839

VRDN
VRDN

VIRIDIAN THERAPEUTICS INC

COM
92790C104
$48.37 M
6 %

3,459,913

COGT
COGT

COGENT BIOSCIENCES INC

COM
19240Q201
$44.70 M
6 %

6,225,641

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 17